NeoGenomics Laboratories expanded Medicare coverage for RaDaR® ST to provide ctDNA-based monitoring of immunotherapy response.
Public source
Publisher name
Public post
Exciting progress for precision oncology and IO therapy. Expanded Medicare coverage for RaDaR® ST brings greater access to ctDNA-based monitoring of immunotherapy respon…
Company
NeoGenomics Laboratories
Answers are in our DNA™
- Industry
- Hospitals and Health Care
- Location
- Fort Myers, US
- Company size
- 1,001–5,000 employees
About NeoGenomics Laboratories
Our vision: A world where every cancer treatment decision is as personal as the patient. Our mission: We take cancer personally. We partner with physicians to deliver actionable insights that guide personalized treatment decisions and improve outcomes -- through a comprehensive oncology portfolio and an unwavering commitment to excellence powered by a team of dedicated experts.
See moreLatest activity
Latest activity from NeoGenomics Laboratories
9 signals
Products & Services
NeoGenomics Laboratories launched Neo Comprehensive® for Myeloid Disorders testing, offering a single test for DNA and RNA alterations in a complete genomic view.
Products & Services
NeoGenomics Laboratories launched PTEN IHC CDx as part of PanTracer Pro, pairing IHC-based PTEN deficiency identification with comprehensive genomic profiling.
Presence & Recognition
NeoGenomics Laboratories presented research on AI-based detection and scoring of TROP2 expression in IHC-stained NSCLC specimens at AACR 2026, along with AI applications for automated phenotyping of multiplex immunofluorescence data.
Discover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
TRIO - Translational Research in Oncology
TRIO - Translational Research in Oncology received guidance from the FDA Oncology Center of Excellence to support broader participation in oncology clinical trials by encouraging more inclusive eligibility criteria across performance status, laboratory values, washout periods, and concomitant medications.
Legal & Regulatory
Guardant Health
Guardant Health announced that the Guardant360 CDx assay was approved by the FDA as a companion diagnostic device to identify patients with breast cancer with ESR1 mutations for treatment with camizestrant.
Legal & Regulatory
Bio-Rad Laboratories
Bio-Rad Laboratories announced the accelerated FDA approval of camizestrant, highlighting the growing clinical importance of ESR1 mutation testing in HR-positive, HER2-negative advanced breast cancer.
Legal & Regulatory
UF Health Cancer Institute
UF Health Cancer Institute reported that the FDA has approved a new first-line treatment combination for adults with advanced, HER2-positive gastric and esophageal cancers.
Legal & Regulatory
Moffitt Cancer Center